Studies on Compatibilty of Rivaroxaban with Pharmaceutical Excipients Using DSC and FTIR Spectrophotometry

Rivaroxaban (RN) is a powerful oral anticoagulant that was recently developed. It was the most commonly prescribed drug during COVID-19 pandemic situations. The goal of this study is to use a differential scanning calorimeter and an FTIR spectrophotometer to investigate the compatibility of rivaroxaban with crospovidone, sodium startch glycolate, magnesium stearate, talc, microcrystalline cellulose, aerosil, HPMC K100 M, and croscarmellose sodium. DSC thermograms, of rivaroxaban and physical mixture of individual pharmaceutical excipient, exhibited the range of transition of the drug in between 224ºC and 232ºC. The FTIR graphs revealed that the wave numbers of rivaroxaban corresponded to all of the selected pharmaceutical excipients. As a result of the DSC and FTIR examinations, it was determined that RN was not interacting with chosen pharmaceutical excipients and that it may be used in future research. The results of the present investigation concluded that these combinations are compatible and can be used for further studies, so as to develop pharmaceutical formulations with rivaroxaban.